Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.73 |
| ▸ | PKM | P14618 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008427 | 0.98 | ALDH1A1 (0.76) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL1712163 | 0.86 | ALDH1A1 (0.57) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL12571006 | 0.86 | ALDH1A1 (0.54) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL2005591 | 0.86 | ALDH1A1 (0.64) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL1711623 | 0.85 | ALDH1A1 (0.60) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL5161908 | 0.85 | ALDH1A1 (0.55) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL2009617 | 0.84 | ALDH1A1 (0.67) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL12570922 | 0.84 | CA12 (0.63) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL2013461 | 0.84 | ALDH1A1 (0.54) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL2004233 | 0.84 | ALDH1A1 (0.67) | ALDH1A1PKMMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137141-B1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | UNIV ABERDEEN (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-1756046-B1 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2009-12-09 | — | — | EP | disclosed |
| EP-1756046-B1 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008114022-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-25 | — | — | WO | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1756046-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | ARSA, SOST, AHR | ALDH1A1 2561/4885PKM 3427/4885MEN1 4647/4885 |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | ARSA, CNKSR1, BCL9L | ALDH1A1 1548/4885PKM 4242/4885MEN1 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.